San Diego, Ca., USA - December 18, 2013, San Diego, Ca., USA - Halozyme Therapeutics, Inc., a biopharmaceutical company, announced that Helen Torley will be joining as president and chief executive officer, effective January 6, 2014.
Article continues below
Dr. Torley will also become a member of Halozyme's Board of Directors. Dr. Torley was most recently Executive Vice President and Chief Commercial Officer at Onyx Pharmaceuticals, a subsidiary of Amgen.
Prior to Onyx, Dr. Torley spent 14 years in management positions at Amgen, first in the Nephrology Business Unit, later in the Bone Health Business Unit.
She held various senior positions at Bristol Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales, and Head of Cardiovascular Global Marketing.
She began her industry career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, overseeing clinical studies across all therapeutic areas, including oncology.
Gregory I. Frost is departing Halozyme.
Dr. Frost co-founded Halozyme in 1999 and has spent more than fifteen years conducting research on the extracellular matrix. During his eleven years at Halozyme, Dr. Frost has led the R&D efforts from discovery through FDA approval for a number of biotechnology products, and he was named President and CEO in December 2010.
From 1998 to 1999, he was a scientist at the Sidney Kimmel Cancer Center (SKCC), where he focused much of his work on studying tumor physiology and developing enzyme platform technologies.
Prior to SKCC, his research in the Department of Pathology at the University of California, San Francisco, led directly to the purification, cloning, and characterization of the human hyaluronidase gene family, and the discovery of several metabolic disorders.
He has authored multiple scientific peer-reviewed and invited articles in the hyaluronidase field and is an inventor on several key patents.
Dr. Frost is a member of the American Association for Cancer Research and the American Society of Clinical Oncology and he is registered to practice before the U.S. Patent and Trademark Office. ■